Search results for "PRESSURE"

showing 10 items of 4493 documents

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Acute changes of systemic parameters in tumour-bearing rats, and of tumour glucose, lactate, and ATP levels upon local hyperthermia and/or hyperglyca…

1991

Arterial blood pressure and relevant parameters of the arterial blood (O2 and CO2 tensions, pH, haematocrit, serum electrolytes and osmolality) were determined in tumour-bearing rats upon local hyperthermia (HT) and/or hyperglycaemia (HG). Tumour heating was performed in a saline bath (44 degrees C) for 120 min; hyperglycaemia was induced by i.v. infusion of 40% glucose solution for 150 min [blood glucose levels: 35-40 mM during heating; total amount of glucose: 1.19 g/100 g body wt.; infusion rates: 0.31 ml (100 g body wt.)-1 min-1 for 2 min, 0.02 ml (100 g body wt.)-1 min-1 for 88 min, and 0.01 ml (100 g body wt.)-1 min-1 for 60 min]. Immediately after treatment, glucose, lactate and ATP …

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyPartial Pressuremedicine.medical_treatmentHemodynamicsBlood PressureStimulationElectrolytesAdenosine TriphosphateInternal medicinemedicineAnimalsLactic AcidInfusions IntravenousSalineHematologyChemistryMusclesOsmolar ConcentrationRats Inbred StrainsHyperthermia InducedNeoplasms ExperimentalGeneral MedicineMetabolismCarbon DioxideHydrogen-Ion Concentrationmedicine.diseaseCombined Modality TherapyRatsOxygenGlucoseEndocrinologyBlood pressureHematocritOncologyHyperglycemiaLactatesArterial bloodJournal of Cancer Research and Clinical Oncology
researchProduct

Influence of Demographic and Lifestyle Variables on Plasma Magnesium Concentrations and Their Associations with Cardiovascular Risk Factors in a Medi…

2020

Several studies have shown that a low magnesium (Mg) intake in the diet is associated with greater cardiovascular risk and greater risk of diabetes. However, the results are not consistent in all populations. To minimize the biases derived from diet measurement, more objective biomarkers of magnesium status have been proposed. Although there is still no ideal biomarker for Mg, several studies have shown that plasma Mg concentrations could be a relatively acceptable biomarker for cardiovascular risk assessment. However, further studies are required to better characterize this marker in different populations. Our aim was to analyze the association between plasma Mg concentrations (measured th…

Blood GlucoseMaleMediterranean dietPhysiologyBlood Pressure030204 cardiovascular system & hematologymagnesiumDiet MediterraneanBody Mass Indexchemistry.chemical_compound0302 clinical medicineAged 80 and overeducation.field_of_studyNutrition and DieteticsdiabetesMediterranean RegionAge FactorsMiddle AgedLipidsQuartileCardiovascular DiseasesCreatinineFemaleWaist Circumferencemediterranean populationlcsh:Nutrition. Foods and food supplyAdultAdolescentPopulationNutritional Status030209 endocrinology & metabolismlcsh:TX341-641Risk AssessmentArticleWhite PeopleHypomagnesemia03 medical and health sciencesYoung AdultSex FactorsDiabetes mellitusmedicineTobacco SmokingHumansAspartate AminotransferaseseducationLife StyleAgedCholesterolbusiness.industrycholesterolmediterranean dietmedicine.diseaseObesityUric AcidCross-Sectional StudieschemistryDiabetes Mellitus Type 2Heart Disease Risk FactorsSpainCase-Control StudiesUric acidbusinessFood Science
researchProduct

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct

Relationship between childhood obesity cut-offs and metabolic and vascular comorbidities: comparative analysis of three growth standards

2013

Background: To compare the association between metabolic and vascular comorbidities and the body mass (BMI)-for-age cut-off criteria from three growth standards [Centers for Disease Control and Prevention (CDC), 2000; World Health Organization (WHO), 2007; Spanish Reference Criteria (Carrascosa Lezcano et al., 2008)] that are used to define being overweight and obese in childhood. Methods: A prospective study was conducted in 137 children (aged 8–16 years). Based on BMI-for-age Z-scores according to WHO cut-offs, 59 participants were obese, 35 were overweight and 43 were normal-weight. All participating children were subsequently reclassified applying the CDC and Spanish Reference Criteria.…

Blood GlucoseMalePediatric Obesitymedicine.medical_specialtyAdolescentmedicine.medical_treatmentNutritional StatusMedicine (miscellaneous)Blood PressureComorbidityOverweightCarotid Intima-Media ThicknessChildhood obesityBody Mass IndexInternal medicinemedicineHumansInsulinProspective StudiesChildProspective cohort studyTriglyceridesMetabolic SyndromeNutrition and Dieteticsbusiness.industryInsulinBody WeightCholesterol HDLnutritional and metabolic diseasesCholesterol LDLOverweightmedicine.diseaseObesityBody HeightNutrition AssessmentBlood pressureCardiovascular DiseasesSpainPhysical therapyFemaleWho criteriamedicine.symptombusinessBody mass indexJournal of Human Nutrition and Dietetics
researchProduct

Prevalence of 'borderline' values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE stu…

2011

Introduction: The prevalence of patients with 'borderline' levels of cardiovascular risk factors has been rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The BORDERLINE study represents a pilot experience to primarily identify the prevalence of 'high-normal' conditions, such as pre-hypertension, lipid and glucose levels in the upper range of normality in the setting of general practice in Italy. Aim: The aim of this study was to evaluate the prevalence of patients with 'borderline' values of cardiovascular risk factors in Italy. Methods: Involved physicians were asked to evaluate the first 20 outpatients, consecutively seen in June 2009. …

Blood GlucoseMaleSettore MED/09 - Medicina InternaGeneral PracticeBlood PressurePilot ProjectsDiseasechemistry.chemical_compoundPrehypertensionRisk FactorsPrevalenceMedicineglucoseeducation.field_of_studycardiovascular risk factors general medicine borderline studiescardiovascular preventionMiddle AgedLipidsItalyCardiovascular Diseaseshigh-normal riskborderline risk high-normal risk cardiovascular prevention global cardiovascular risk blood pressure cholesterol glucoseFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyCardiovascular risk factorsPopulationDiastoleRisk AssessmentPharmacotherapyInternal medicineInternal MedicineHumansborderline riskglobal cardiovascular riskeducationPsychiatryAgedDyslipidemiasGlucose Metabolism DisordersChi-Square Distributionbusiness.industryCholesterolcholesterolMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREborderline risk; high-normal risk; blood pressure; global cardiovascular risk; glucose; cardiovascular prevention; cholesterolHealth SurveysBlood pressurechemistryArterial Hypertension Epidemiology Cardiovascular RiskbusinessBody mass indexBiomarkers
researchProduct

Short Sleep Duration Is Related to Emerging Cardiovascular Risk Factors in Obese Children

2015

Objective: The aim of the present study was to evaluate the influence of sleep duration on cardiovascular risk factors in obese children. Methods: Cross-sectional analysis of 90 obese children ages 7 to 16 years. Anthropometric and clinical evaluation with specification of dietary and lifestyle habits was carried out during an office visit. Sleep duration was evaluated by the BEARS (B = bedtime issues, E = excessive daytime sleepiness, A = night awakening, R = regularity and duration of sleep, S = snoring) questionnaire on children's sleep characteristics. Sleep time adequacy by age was assessed according to the criteria of the National Sleep Foundation. Biochemical blood variables indicati…

Blood GlucoseMaleSleep Wake Disorderscardiovascular riskPediatric ObesityPediatricsmedicine.medical_specialtyobesityAdolescentCross-sectional studyThyrotropinBlood PressureBody Mass IndexAdipokinesRisk FactorsSurveys and QuestionnairesmedicineHumansInsulinDuration (project management)ChildHomocysteineMetabolic Syndromebusiness.industryGastroenterologyhomocysteineAnthropometrymedicine.diseaseretinol-binding proteinObesitySleep in non-human animalsC-Reactive ProteinCross-Sectional StudiesBlood pressureEl NiñoCardiovascular DiseasesObesity AbdominalPediatrics Perinatology and Child Healthsleep durationFemaleSleepbusinessRetinol-Binding Proteins PlasmaBody mass index
researchProduct

Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: A model related to metabolic syndrome

2011

Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases. The aim of this work was to analyze the time course of dimethylarginine compounds and oxidative stress levels and the relationship between these and cardiovascular function in fructose-hypertensive rats.90 male Sprague-Dawley rats were randomized into 2 groups, fed for 3 months with standard (C) chow supplemented or not with fructose (F, 60%). After sacrifice at different weeks (W), the aorta and plasma were harvested to assess the vascular and biochemical parameters. Our …

Blood GlucoseMaleTime FactorsVasodilator AgentsNitric Oxide Synthase Type IIBlood Pressure030204 cardiovascular system & hematologymedicine.disease_causeRats Sprague-Dawleychemistry.chemical_compound0302 clinical medicineHeart RateEnzyme InhibitorsAortaComputingMilieux_MISCELLANEOUSMetabolic Syndrome0303 health sciencesOxidase testVasodilationNAD(P)H oxidaseHypertensionCardiology and Cardiovascular Medicinemedicine.medical_specialtyFructoseArginine03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicine.arterymedicineAnimals030304 developmental biologyAortaDose-Response Relationship Drugbusiness.industryVascular diseaseBody WeightNADPH OxidasesFructosemedicine.diseaseRatsDisease Models AnimalOxidative StressEndocrinologychemistryTyrosineMetabolic syndromebusinessAsymmetric dimethylarginineOxidative stressAtherosclerosis
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial

2021

Abstract Background Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage. Aims We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatmen…

Blood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaTime FactorsEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesBlood PressureType 2 diabetesGastroenterologylaw.inventionRandomized controlled triallawPulse wave velocityOriginal InvestigationDiabetesMiddle AgedLipidsVasodilationTreatment OutcomeItalyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyRecombinant Fusion ProteinsIncretinsGlucagon-Like Peptide-1 ReceptorVascular StiffnessDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsDulaglutideAngiologyAgedVascular healthGlycated Hemoglobinbusiness.industrymedicine.diseasedulaglutide diabetes arterial stiffnessImmunoglobulin Fc FragmentsBlood pressureDiabetes Mellitus Type 2lcsh:RC666-701Arterial stiffnessDulaglutidebusinessBiomarkersCardiovascular Diabetology
researchProduct